-- Krishnaswamy Yeleswaram, Chief Development Officer, on April 10, 2026, sold 19,865 shares in Rapport Therapeutics (RAPP) for $695,823. Following the Form 4 filing with the SEC, Yeleswaram has control over a total of 266,651 common shares of the company, with 266,651 shares held directly.
SEC Filing:
https://www.sec.gov/Archives/edgar/data/2012593/000119312526154908/xslF345X05/ownership.xml